Spectral Diagnostics Inc. (OTCMKTS:EDTXF - Get Free Report) was up 0.7% during trading on Friday . The stock traded as high as $0.62 and last traded at $0.62. Approximately 8,059 shares were traded during trading, an increase of 18% from the average daily volume of 6,819 shares. The stock had previously closed at $0.62.
Spectral Diagnostics Stock Down 4.7%
The firm has a 50 day moving average of $0.61 and a 200 day moving average of $0.51. The firm has a market cap of $170.08 million, a price-to-earnings ratio of -8.51 and a beta of 0.22.
Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.40 million during the quarter.
Spectral Diagnostics Company Profile
(
Get Free Report)
Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
Further Reading
Before you consider Spectral Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spectral Diagnostics wasn't on the list.
While Spectral Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
